Apellis signs royalty purchase deal with Sobi for Aspaveli

J Studios

Apellis Pharmaceuticals (NASDAQ:APLS) announced a new agreement with Sobi (SWOBF) (OTCPK:SWOBY) involving a capped royalty purchase related to Aspaveli, its blood disorder treatment.

In this arrangement, Apellis will obtain up to $300M in return for 90% of its future royalties outside the U.S. for